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Abstract
Background: Many ocular medications are prescribed for paediatric patients, but the evidence for their rational
use is very scant. This study was planned to compare the availability and the licensing status of ocular medications
marketed in Italy, the United Kingdom (UK), and the United States of America (USA) related to the amount of
published and un-published RCTs testing these drugs in the paediatric population.
Methods: A quantitative analysis was performed to evaluate the number of ocular medications with a paediatric
license in Italy, the UK, and the USA. A literature search was also performed in MEDLINE, EMBASE, and The
Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) on ophthalmic
pharmacological therapy in children aged < 18 years, published up to December 2010. A search in the
international clinical trial registries, the list of paediatric investigation plans (PIPs) approved by European Medicines
Agency (EMA), and the table of medicines with new paediatric information approved by Food and Drug
Administration (FDA) was also performed.
Results: In all, of 197 drugs identified, 68 (35%) single drugs are licensed for paediatric use at least in one
considered country, while 23 (12%) were marketed in all three countries. More specifically, in Italy 43 single drugs
(48% of those marketed) had a paediatric license, while 39 (64%) did in the UK and 22 (54%) did in the USA. Only
13 drugs were marketed with a paediatric license in all countries.
The percentage of drugs licensed for paediatric use and for which at least one RCT had been performed ranged
between 51% in Italy and 55% in the USA. No published RCTs were found for 11 (48%) drugs licensed for
paediatric use in all three countries. In all, 74 (35%) of the retrieved RCTs involved mydriatic/cycloplegic
medications.
A total of 62 RCTs (56% completed) on 46 drugs were found in the international clinical trial registries. Cyclosporin
and bevacizumab were being studied in many ongoing trials. Twenty-six drugs had new paediatric information
approved by FDA based on new paediatric clinical trials, while only 4 PIPs were approved by EMA.
Conclusions: There is a pressing need for further research and clinical development in the pediatric ophthalmic
area, where effective up-to-date treatments, and additional research and education on use in children, remain
priorities.
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Background
Many drugs on the market labelled for adult use contain
no information on paediatric use because their safety and
efficacy have not been well studied in paediatric patients
[1]. Many widely used drugs therefore include disclaimers
stating that the paediatric use is “not recommended”.
Despite the prevalence of eye disease in early childhood
(in the United Kingdom, by 3 years of age 5.7% of chil-
dren had had ≥ 1 eye condition, 0.24% of which asso-
ciated with visual impairment) [2] more than in other
paediatric areas, evidence for the rational use of ocular
medicines in these patients is very scant.
Many ocular medications are used in children to treat
common bacterial and viral infections, inflammation and
allergy, uveitis and glaucoma, as well as other conditions
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data regarding their safety and effectiveness in the pae-
diatric population are sparse. In 2000, a review of the 98
most commonly used or prescribed topical ophthalmic
drugs found that only 51% provided information on pae-
diatric use [4]. Without adequate paediatric labelling
information, practitioners treating eye disease in chil-
dren may be forced to prescribe ocular medications in
an “off-label” manner, placing their paediatric patients at
risk for serious adverse reactions [5,6].
Children are not small adults. Statements regarding
p a e d i a t r i cd r u gu s em u s tb ea g e - s p e c i f i ct oi n d i c a t ef o r
which group a drug has been studied: newborns, infants,
pre-school children, school-age children, and adolescents.
These groups differ not only in size and body weight but
in physiology and metabolism as well [7]. Children, in
particular infants and neonates who have thin eye mem-
branes, may be particularly vulnerable to systemic effects
of topical ophthalmic drugs as the doses used are often
not weight-adjusted and are similar to doses used in
adults. Systemic absorption may have a greater impact in
children than in adults due to their lower body mass,
altered metabolic capacity, and an immature blood brain
barrier, leading to potentially higher plasma levels for a
longer period of time and to a much greater risk of
serious systemic side effects [8].
In addition to these differences, other characteristics
unique to the paediatric population include the lack of
commercially available dosage forms and concentrations
appropriate for paediatric patients and the lack of pub-
lished research on the pharmacokinetics and clinical use
of new drugs [9]. The result is the high frequency of
serious medication errors.
A study was planned to compare the availability and
the licensing status of ocular medications marketed in
Italy, the United Kingdom (UK), and the United States of
America (USA) related to the amount of published and
un-published RCTs testing these drugs in the paediatric
population.
Methods
Ocular medications were identified and classified accord-
ing to the International Anatomic-Therapeutical-Chemi-
cal classification system (ATC) [10] as S01: antibiotics,
antivirals, anti-allergy drugs,n o n - s t e r o i d a lanti-inflam-
matory drugs (NSAIDs), steroids, diagnostic agents,
lubricants, glaucoma medications, local anaesthetics, and
vascular endothelial growth factor inhibitors (anti-VEGF
drugs) and combinations. A quantitative analysis was
performed to record the number of ophthalmic drugs
available on the market and those approved for paediatric
use in Italy, the UK, and USA. Data on the licensing sta-
tus of individual drugs were obtained by consulting
national formularies: Italy’s Repertorio Farmaceutico Ita-
liano (Refi) [11], the UK’s British National Formulary
(BNF) [12], and the USA’sP h y s i c i a n s ’ Desk Reference
®
(PDR
®) [13].
In order to collect randomized controlled trials (RCTs)
on safety and efficacy of ophthalmic drugs in the paedia-
tric population, a bibliographic search for ophthalmologi-
cal therapy in children aged up to 18 years in the
MEDLINE (1967 - December 2010), EMBASE (1975 -
December 2010), and Cochrane Central Register of Con-
trolled Trials (1967 - December 2010) databases was
performed. The MeSH search terms and additional
keywords used in the search strategy were: child/infant/
newborn/adolescent, ophthalmology, drug therapy, and
randomized controlled trials, limiting the results to
human. To make the search more complete, the terms
were searched for both in the database dictionaries and
through the free text search option that covered the arti-
cles’ titles and abstracts. All the references retrieved were
collected and analyzed using the software program Refer-
ence Manager, version 11 (Institute for Scientific Informa-
tion, Berkeley, California). The titles and abstracts were
screened independently by two reviewers (FF and AC) to
assess the relevance of the studies. Contrasting results
were reviewed by a third person (MB).
We also searched for guidelines concerning paediatric
ophthalmology management in MEDLINE and EMBASE,
in the National Guidance Clearinghouse, National Library
of Guidelines Specialist Library, National Institute for Clin-
ical Excellence (NICE), Australian National Health and
Medical Research Council, Canadian Medical Association
InfoBase and New Zealand Guidelines Group databases,
and on the American Academy of Pediatrics, Canadian
Pediatric Society, and Royal College of Pediatrics websites.
In addition, a search for paediatric clinical trials on
ocular medications in the World Health Organization’s
International Clinical Trials Registry Platform (ICTRP)
[14], the ClinicalTrials.gov registry [15], and the Interna-
tional Standard Randomized Controlled Trial Number
Register (ISRCTN) [16] was performed in order to find
which of these drugs are under paediatric investigation.
Furthermore, the list of paediatric investigation plans
(PIPs) approved by EMA [17], the “List of the active sub-
stances included in the work-sharing procedure in accor-
dance with Articles 45 and 46 of the European Paediatric
Regulation [18], and the FDA’s “Table of Medicines with
new paediatric information”,al i s to fd r u g sa p p r o v e df o r
paediatric use resulting from the paediatric clinical trials
performed in response to paediatric legislative initiatives
[19], and the updated priority list for studies into off-
patent paediatric medicinal products [20], were also con-
sulted in order to assess if there is a gap between research
and clinical practice.
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Quantitative analysis
A total of 197 ocular medications were reported in the
2010 ATC index, respectively, 88 (45%), 63 (31%), and
41 (21%) of which were marketed in Italy, the UK, and
the USA.
In all, 68 (35%) single drugs are licensed for paediatric
use in at least one considered country, while 23 drugs
(12%) were marketed in all three countries. More specifi-
cally, in Italy 43 single drugs (48% of those marketed) had
a paediatric license, while 39 (64%) did in the UK and 22
(54%) did in the USA. Only 13 drugs were marketed with
a paediatric license in all the countries (Table 1). Only 3
licensed drugs appear in the World Health Organization
(WHO) list of paediatric essential drugs. Tetracycline as
1% eye ointment and adrenaline as 2% eye drops, consid-
ered essential drugs for children, were not licensed for
paediatric use in any country.
Fifteen single drugs and six combinations (mainly anti-
infective, anti-inflammatory, and anti-allergy medications)
were licensed for paediatric use only in Italy, while 16 sin-
gle drugs and 8 combinations were licensed only in the
UK (mainly local anaesthetics and lubricants), and 2 single
drugs and 8 combinations only in the USA (mainly anti-
infective medications). Almost all anti-allergy medications
and combinations had a paediatric license in all three
countries, while no local anaesthetics are licensed for pae-
diatric use in Italy and USA and no NSAIDs are in the
UK.
Wide differences were found in the age groups for which
the drugs were licensed and only for 6 drugs the age range
is the same or similar in all countries.
Qualitative analysis
Bibliographic search
The bibliographic search produced 158 RCTs on 69 sin-
gle drugs and combinations, involving a total of 18,816
children (Table 2). The percentage of drugs licensed for
paediatric use with at least one RCT ranged between 51%
in Italy and 55% in the USA. No published RCTs were
found for 11 (48%) ocular medications licensed for pae-
diatric use in all three countries.
I na l l ,7 4r e t r i e v e dR C T s( 3 5 % )r e g a r d e dm y d r i a t i c /
cycloplegic medications, mainly antimuscarinic agents. In
particular, 31 RCTs involving 3,530 children belonging to
all age groups studied atropine as eye drops 1%, a drug
licensed for paediatric use only in the UK (≥ 3m o n t h s ) .I n
addition, 3 studies were available on pirenzepine, a drug
not licensed for paediatric use in any country.
Regarding the treatment of allergic conjunctivitis, 49
(23%) RCTs on 11 drugs were found: 22 studies involved
6 anti-histamine agents (azelastine, bepotastine, emedas-
tine, ketotifen, levocabastine, and olopatadine) tested in
children ≥ 3 years, and 9 RCTs involved 3 mast cell stabi-
lizers, such as lodoxamide, cromoglicate, and nedocromil,
in children ≥ 4 years. Bepotastine is the only drug unli-
censed for paediatric use in all considered countries.
A total of 43 RCTs (21%) concerned 20 antibacterial
agents and their combinations, 8 of them (40%) not
licensed for paediatric use in any country considered, such
as the fluoroquinolone besifloxacin as eye suspension 2%,
tested in 3 RCTs in children older than one year. Among
the six combinations studied 3 were licensed for paediatric
use in the UK and 2 in the USA, while none in Italy. In
addition, the anti-infective agent povidone-iodine, licensed
for use in children older than 1 month, was studied only
in Italy in 3 RCTs.
Among the medications commonly used in ophthalmic
surgical procedures (e.g. strabismus surgery) there were 7
local anaesthetics (proparacaine, not licensed for paediatric
use in any country was the drug most studied), 3 steroids
(dexamethasone, fluorometholone, and rimexolone), and 3
NSAIDs (diclofenac, ketorolac, and flurbiprofen).
Ten RCTs regarded anti-glaucoma agents: 7 were on 3
beta-blockers, 2 on carbonic anhydrase inhibitors, and
the last one on an acethylcholinesterase inhibitor,
echothophate iodide. The most studied drug is timolol, a
beta-bloker licensed for use in children older than 1
month only in Italy, as well as the carbonic anhydrase
inhibitor dorzolamide.
Phenylephrine, the only decongestant agent studied,
licensed for paediatric use in all countries considered, was
involved in 11 RCTs, in which it was used in combination
with a mydriatic/cyclopegic agent for eye examinations in
children. In one RCT involving 10 neonates, phenylephr-
ine was used alone.
Guidelines
Eight guidelines on pharmacological management of eye
diseases in children were found: they addressed acute bac-
terial conjunctivitis [21], amblyopia [22,23], strabismus
[24], glaucoma [25], retinopathy of prematurity (ROP)
[26,27], and prophylaxis of neonatal ophthalmia [28]
(Table 3). Those concerning screening methods for diag-
nosing eye diseases in the paediatric population without
drug use were not reported.
Five guidelines (2 regarding ROP, 2 regarding amblyo-
pia, and 1 regarding strabismus) recommended drug use
only for screening or post-surgical therapy, and not for
the pharmacological management of the disease in
childhood.
Almost all of the drugs listed in the guidelines are not
licensed for use in children in any country considered,
especially for prophylaxis of neonatal ophthalmia (no
drug licensed), for the medical management of childhood
glaucoma (5 out of 8 drugs are unlicensed) and acute
bacterial conjunctivitis (8 out of 22 drugs are unlicensed).
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Pharmaco-therapeutic Group Drug name Licence Status RCTs
IT UK USA Published Non-
published
ANTI-ALLERGY MEDICATIONS 14/12* 8/8* 11/10* 34 5
Anti-histamine agent Azelastine ≥ 4 yrs ≥ 12 yrs ≥ 3 yrs 4 -
Emedastine ≥ 3 yrs ≥ 3 yrs ≥ 3 yrs 1 -
Epinastine ≥ 12 yrs ≥ 12 yrs ≥ 3 yrs - -
Ketotifen ≥ 3 yrs ≥ 3 yrs ≥ 3 yrs 5 3
Levocabastine all NA** NA 6 -
Olopatadine ≥ 3 yrs ≥ 3 yrs ≥ 3 yrs 4 1
Mast cell stabilizer Spaglumic acid all NA NA - -
Lodoxamide all ≥ 4 yrs > 2 yrs 1 -
Nedocromil sodium ≥ 6 yrs ≥ 6 yrs ≥ 3 yrs 5 -
Sodium cromogligate ns** all NA 6 -
Pemirolast NA NA ≥ 3 yrs - -
Decongestant (Sympathomimetic agent) Naphazoline ≥ 10 yrs NA nl - 1
Oxymetazoline ≥ 3 yrs NA ≥ 6 yrs - -
Tetryzoline ≥ 3 yrs NA ≥ 6 yrs - -
ANTI-ALLERGY COMBINATIONS 3/3 1/1 2/2 0 0
Anti-histamine agent + Decongestant Antazoline + Xylometazoline NA ≥ 5 yrs NA - -
Chlorpheniramine +
Tetryzoline
≥ 3 yrs NA NA - -
Pheniramine + Tetryzoline ≥ 3 yrs NA NA - -
Mast cell stabilizer + Decongestant Cromoglicate + Tetryzoline ≥ 3 yrs NA NA - -
Astringent + Decogestant Zinc sulfate + Tetryzoline NA NA ≥ 6 yrs - -
Decogestant + Lubricants Tetryzoline + Povidone +
Dextran 70 + Polyethylene
glycol 400
NA NA ≥ 6 yrs - -
ANTI-GLAUCOMA MEDICATIONS 23/6 14/1 6/1 4 3
Beta-blocker Timolol > 1 m nl** nl 4 2
Carbonic anhydrase inhibitor Dorzolamide all nl ns -
Sympathomimetic agent (selective a2 -
agonist)
Apraclonidine ≥ 12 yrs ≥ 12 yrs nl - -
Brimonidine ≥ 12 yrs NA ≥ 2 yrs - 1
Clonidine ns NA NA - -
Parasympathomimetic (colinergic) agent Aceclidine ≥ 3 yrs NA NA - -
Pilocarpine ≥ 3 yrs nl Nl - -
ANTI-GLAUCOMA COMBINATIONS 2/1 1/0 2/2 1 0
Beta-blocker + Carbonic anhydrase inhibitor Timolol + Dorzolamide ≥ 2 yrs nl ≥ 2 yrs 1 -
Beta-blocker + Sympathomimetic agent Timolol + Brimonidine nl NA ≥ 2 yrs - -
ANTI-INFLAMMATORY MEDICATIONS 16/8 8/5 5/2 16 6
Non-Steroidal Anti-Inflammatory Drug
(NSAID)
Diclofenac ≥ 3 yrs nl nl 4 1
Indomethacin ≥ 3 yrs NA NA - -
Ketorolac NA nl ≥ 3 yrs 3 -
Steroid agent Betamethasone NA all NA - -
Desonide > 1 m NA NA - -
Dexamethasone > 1 m all nl 6 2
Fluorometholone ≥ 2 yrs ≥ 2 yrs ≥ 2 yrs 3 1
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Hydrocortisone > 1 m all NA - -
Prednisolone NA all nl - 2
Clobetasone >1 m NA NA - -
Steroid agent + Decongestant Fluorometholone +
Tetryzoline
≥ 2 yrs NA NA - -
Clobetasone + Tetryzoline ns NA NA - -
ANTI-INFECTIVE MEDICATIONS 21/13 9/9 10/7 27 3
Antibacterial agent Chloramphenicol ≥ 3 yrs all NA 7 -
Fusidic acid ns all NA 3 -
Propamidine isetionate NA all NA - -
Aminoglycoside Gentamycin ≥ 3 yrs all >1yr 2 1
Neomycin NA all NA - -
Netilmycin > 1 m NA NA - -
Tobramycin ≥ 1y r N A n l 3 -
Quinolone Ciprofloxacin all ≥ 1y r ≥ 1y r 2 -
Gatifloxacin NA NA ≥ 1y r -
Levofloxacin ≥ 1y r ≥ 1y r ≥ 1y r 2 -
Lomefloxacine ≥ 1y r N A N A - -
Moxifloxacin ≥ 1m n l ≥ 1y r 3
Ofloxacin nl
ophtalmia
neonatorum > 1m ≥ 1y r 1
-
Antiviral agent Acyclovir all all nl - -
Idoxuridine ≥ 3 yrs NA NA - -
Trifluridine all NA ≥ 6 yrs - -
Other anti-infective agent Povidone - Iodine > 1 m NA nl 4 2
ANTIBACTERIAL COMBINATIONS 9/2 6/3 4/1 3 0
Antibacterials Polimyxin B + Trimethoprim NA all > 2 ms 1 -
Polimyxin B + Bacitracin NA all nl 1 -
Neomycin + Polymyxin B +
Gramicidin
NA ≥ 2 yrs nl - -
Neomycin +
Chloramphenicol
ns NA NA - -
Antibacterial + Steroid Neomycin + Polymyxin B +
Dexamethasone
nl all ≥ 2 yrs - -
Neomycin + Polymyxin B +
Hydrocortisone
NA NA ns - -
Neomycin +
Chloramphenicol +
Hydrocortisone
ns NA NA - -
Neomycin + Prednisolone ns all NA - -
Neomycin + Fluocinolone ns NA NA - -
Neomycin + Betamethasone NA all NA 1 -
Tobramycin +
Dexamethasone
nl NA ≥ 2 yrs - -
Prednisolone +
Sulphacetamide
NA NA ≥ 6 yrs - -
Tobramycin +
Fluorometholone
NA NA ≥ 2 yrs - -
Antibacterial + Steroid + Decongestant Neomycin + Gramicidin +
Tetryzoline +
Dexamethasone
≥ 3 yrs NA NA - -
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used in a off label manner and that the majority of data
on these medications are from adult studies.
Finally, no guidelines on the pharmacological treat-
ment of allergic conjunctivitis were found.
Search for the paediatric RCTs in registries
A search performed in the World Health Organization’s
International Clinical Trials Registry Platform (ICTRP),
the ClinicalTrials.gov registry, and the International
Standard Randomized Controlled Trial Number Register
(ISRCTN) found 46 ocular medications currently under
paediatric investigation in 62 RCTs (56% of which com-
pleted). Cyclosporin, an immunosuppressant agent, and
bevacizumab, a humanized monoclonal antibody, were
the drugs involved in the most studies: 7 RCTs testing
cyclosporine in the treatment of keratoconjunctivitis (4),
Table 1 Paediatric licensing status and number of RCTs related to ocular medications (Continued)
Betamethasone +
Sulphacetamide + Tetryzoline
≥ 2 yrs NA NA - -
MYDRIATIC/CYCLOPLEGIC MEDICATIONS 7/4 6/5 2/1 55 3
Antimuscarinic agent Cyclopentolate ≥ 3 yrs > 3 ms all 14 -
Homatropine ns > 3 ms nl - -
Tropicamide > 1 m all NA 10 -
Atropine ns > 3 ms (nl
uveitis)
NA 31 3
Ibopamine all NA NA - -
Decongestant (Sympathomimetic agent) Phenylephrine ≥ 12 yrs All (nl 10%
drops)
NA 2 -
PERI-OPERATIVE MEDICATIONS 2/0 4/4 1/0 4 0
Local anaesthetic Lidocaine nl all nl 2 -
Oxybuprocaine ns all NA 1 -
Proxymetacaine NA all NA - -
Tetracaine NA all NA 1 -
LUBRICANTS AND ASTRIGENTS 5/0 10/5 4/0 0 0
Ocular lubricant and astringent Polyvinyl alcohol Ns all NA - -
Carmellose sodium ns all NA - -
Hydroxyethylcellulose NA all NA - -
Paraffin NA all NA - -
Sodium hyaluronate ns all NA - -
Hypromellose NA all nl - -
LUBRICANT COMBINATIONS 0/0 2/2 6/2 0 0
Lubricants Hypromellose + Glycerin NA NA all - -
Hypromellose + Dextran 70 NA all nl - -
Hypromellose + Glycerin +
Polyethylene glycol 400
NA NA ≥ 6 yrs - -
Lubricant + Steroid agent Hypromellose +
Dexamethasone
NA all NA - -
OTHER OCULAR MEDICATIONS 2/1 2/2 2/1 0 0
Hypertonic agent Sodium chloride NA all Nl - -
Ocular diagnostic agent Fluorescein ns all NA - -
Topical immunomodulator Cyclosporine 0.05% NA NA ≥ 16
yrs
--
Other ocular agent Heparin > 1 m NA NA - -
TOTAL SINGLE DRUGS 68 88/43 61/39 41/22 140 20
TOTAL COMBINATIONS 29 16/7 10/6 14/7 4 -
NOTE: Only drugs with a paediatric licence at least in one country are listed. The drugs in bold are listed in the WHO model list of essential medicines for
children.
* N° drugs marketed/N° drugs marketed with paediatric licence
** ns: not specified; nl: not licensed for paediatric use; NA: not authorised
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Pharmaco-therapeutic Group Drug name Formulation N° RCTs N°
Children
Age
range
MYDRIATIC/CYCLOPLEGIC MEDICATIONS 74
(35%)
Antimuscarinic agent Atropine eye drops 1% 31 3530 all
Cyclopentolate eye drops 0.5% 2 28 ≤ 13 yrs
eye drops 1% 11 181 ≤ 16 yrs
Tropicamide eye drops 1% 9 348 all
Pirenzepine ophthalmic gel 1% 3 276 6 - 12 yrs
Cyclopentolate/Tropicamide eye drops 1%/1% 6 176 all
Sympathomimetic agent Phenylephrine eye drops 2.5% 1 10 ≤ 1m
Antimuscarinic agent + Sympathomimetic
agent
Tropicamide/Phenylephrine eye drops 1%/2.5% 3 92 ≤ 1m
eye drops 0.5%/2.5% 2 51 ≤ 8 yrs
eye drops 0.5%/0.5% 1 12 3-11 yrs
Cyclopentolate/
Phenylephrine
eye drops 1%/2.5% 2 30 ≤ 6 yrs
eye drops 0.2%/1% 3 99 ≤ 1m
ANTI-INFECTIVE MEDICATIO NS 51
(24%)
Antibacterial agent Chloramphenicol eye drops 0.5% 7 1664 ≤ 12 yrs
Azithromycin eye drops 1% 1 335 ≥ 1y r
eye drops 1.5% 2 542 ≥ 1y r
Tetracycline eye drops 1% 2 518 1- 10 yrs
eye ointment 1% 2 218 ≥ 6m s
Besifloxacin eye suspension 0.6% 3 1124 ≥ 1yr
Fusidic acid eye drops 1% 3 594 ≤ 2 yrs
Moxifloxacin eye drops 0.5% 3 645 all
Tobramycin eye drops 3 741 ≤ 12 yrs
Ciprofloxacin eye drops 0.3% 2 193 ≤ 12 yrs
Levofloxacin eye drops 0.5% 2 106 1-16 yrs
Gentamycin eye ointment 2 117 ≤ 12 yrs
Erythromycin eye drops 1 110 ≤ 1m
eye ointment 1 24 ≤ 1y r
Ofloxacin eye drops 0.3% 1 23 ≥2 yrs
Oxytetracycline eye drops 1% 1 450 ≤ 1m
Sulphacetamide eye drops 10% 1 14 ≤ 1m
Antibacterials combinations Polymixin B/Oxytetracycline eye ointment 2 132 2-10 yrs
Polymixin B/Bacitracin eye ointment 1 66 ≥ 1m
Polymixin B/Trimethoprim eye drops 1 28 all
Antibacterial agent + NSAID Gentamycin/Diclofenac eye drops 1 12 ≤ 12 yrs
Antibacterial agent + Steroid agent Neomycin/Betamethasone eye drops 1 12 ≤ 12 yrs
Tobramycin/Dexamethasone eye drops 1 28 4-10 yrs
Antifungal agents Miconazole eye suspension 1% 1 12 ≥ 15 yr
Econazole/Miconazole eye suspension 1%/1% 1 7 ≥ 15 yr
Other anti-infective eye preparation Povidone-iodine eye drops 2.5% 4 3132 ≤ 1y r
Silver nitrate eye drops 1% 1 450 ≤ 1m
ANTI-ALLERGY MEDICATIONS 31
(15%)
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Anti-histamine agent Levocabastine eye suspension 0.5% 6 174 ≥ 3 yrs
Ketotifen eye drops 0.025% 5 522 ≥ 3 yrs
Olopatadine eye drops 0.2% 4 99 ≥ 3 yrs
Azelastine eye drops 0.02% 4 132 ≥ 4 yrs
Bepotastine eye drops 1% 1 36 ≥ 10 yrs
eye drops 1.5% 1 36 ≥ 10 yrs
Emedastine eye drops 0.05% 1 - 3-16 yrs
Mast cell stabilizer Lodoxamide eye drops 0.1% 1 15 ≥ 6 yrs
Cromoglycate eye drops 2% 4 128 ≥ 4 yrs
eye drops 4% 1 30 ≥ 16 yrs
Nedocromil eye drops 2% 3 85 ≥ 4 yrs
ANTI-INFLAMMATORY MEDICATIONS 18 (9%)
Corticosteroid Dexamethasone eye drops 0.1% 6 159 all
Fluorometholone eye drops 0.1% 3 52 ≤ 10 yrs
Rimexolone eye drops 1% 1 22 4 - 8 yrs
NSAID Diclofenac eye drops 0.1% 4 93 ≥ 2 yrs
Ketorolac eye drops 0.5% 3 70 ≤ 12 yrs
Flurbiprofen eye drops 1 50 ≥ 5 yrs
ANTIGLAUCOMA MEDICATIONS 10 (5%)
Beta-blocker Timolol eye drops 0.25% 2 44 7-13 yrs
eye drops 0.5% 1 12 ≥ 14 yrs
gel-forming solution
0.25%
13 5 ≤ 6yrs
gel-forming solution 0.5% 1 36 ≤ 6yrs
Betaxolol eye suspension 0.25% 1 52 ≤ 6 yrs
Levobetaxolol eye suspension 0.5% 1 46 ≤ 6 yrs
Carbonic anhydrase inhibitor Brinzolamide eye suspension 1% 1 32 ≤ 6 yrs
Dorzolamide eye drops 2% 1 56 ≤ 6 yrs
Acetylcholinesterase inhibitor Echothophate iodide eye drops 1 20 -
PERI-OPERATIVE MEDICATIONS 18 (9%)
Local anaesthetic agent Bupivacaine subconjuntival infiltration 2 38 5-10 yrs
eye drops 0.5% 1 17 3-6 yrs
Proparacaine eye drops 0.5% 3 58 ≤ 1m
Lidocaine eye drops 2% 1 10 3 - 14 yrs
ophthalmic gel 2% 1 24 3-12 yrs
Amethocaine eye drops 0.5% 2 45 2 - 8 yrs
Levobupivacaine eye drops 1 13 1 - 16 yrs
Oxybuprocaine eye drops 0.4% 1 20 3-8 yrs
Tetracaine eye drops 1% 1 44 1-12 yrs
Sucrose eye drops 1 11 ≤1m
Chemotherapeutic agents Mitomicyn C eye drops 0.02% 1 10 ≥ 6 yrs
ocular injection 0.4% 1 7 ≥ 6 yrs
5-fluorouracil ocular injection 1 4 ≤ 12 yrs
Mitomicyn C/5-fluorouracil ocular injection 1 4 ≤ 12 yrs
OTHER DRUGS 7 (3%)
Vernal keratoconjunctivitis Cyclosporine eye drops 2% 1 14 5-16 yrs
eye drops 1.25% 1 20 5-14 yrs
eye drops 1% 1 32 5-14 yrs
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Mipragoside ophthalmic gel 0.5% 1 12 5-20 yrs
ROP therapy Bevacizumab intravitreal injection 1 7 ≤ 1m
Esotropia Botulinum toxin ocular injection 1 27 6-12 yrs
Dacryocystitis Herba houttuyaniae eye drops 1 268 ≤ 1m
TOTAL (69 single drugs & combinations) 209 18,816
NOTE: the total is higher than the sum of the RCTs (158) because some drugs were tested in more than one trial. The references to RCTs are available upon
request to the corresponding author.
Table 3 Summary of guidelines on pharmacological therapy of ocular disease in the paediatric population
Ref. Organisation Title Disease Quality
of
evidence
Treatment (Licensing status) Country Year
[41] National Guideline
Clearinghause (NGC)
Guidelines for the
treatment and
management of acute
bacterial conjunctivitis in
children and adults.
Acute bacterial
conjunctivitis
I Topical antibiotic therapy:
￿ Norfloxacin 0.3% (nl)
￿ Ciprofloxacin 0.3%
￿ Ofloxacin 0.3%
￿ Levofloxacin 0.5% (nl UK, nl USA)
￿ Lomefloxacin 0.3%
￿ Moxifloxacin 0.5% (nl UK)
￿ Gatifloxacin 0.3% (nl IT, nl UK)
￿ Chloramphenicol 0.5% (nl USA)
￿ Sulfacetamide Sodium 10% (nl)
￿ Erythromycin 0.5% (nl)
￿ Gentamicin Sulfate 0.3% (nl)
￿ Trimethoprim Sulfate/Polymyxin B
10000 U/1 mg/mL (nl IT)
￿ Fusidic acid 0.1% (nl IT, nl USA)
￿ Tobramycin 0.3% (nl UK, nl USA)
￿ Povidone-iodine 1.25% (nl UK, nl
USA)
￿ Bacitracin (nl)
Ocular steroids and steroid-
antibiotic:
￿ Prednisolone (nl IT, nl USA)
￿ Fluorometholone 0.1%/
sulfacetamide sodium 10% (nl)
￿ Fluorometholone 0.1%
￿ Neomycin/polymyxin B/
dexamethasone 0.1% (nl IT)
￿ Gentamicin 0.3%/prednisolone
acetate 0.1% (nl)
￿ Tobramycin 0.3%/dexamethasone
0.1% (nl)
USA 2005
[34] Canadian Paediatric Society Recommendations for
the prevention of
neonatal ophthalmia
Prophylaxis to
prevent
neonatal
ophthalmia due
to N
gonorrhoeae
III ￿ Silver nitrate 1% eye drops (nl)
￿ Erythromycin 0.5% ointment (nl)
￿ Tetracycline 1% ointment (nl)
Canada 2002
(Rev.
2009)
[29] Moore W. and Nischal K.K. Pharmacologic
management of
glaucoma in childhood
Glaucoma I ￿ Β-Blockers: Betaxolol 0.25% (nl)
￿ Carbonic Anhydrase Inhibitors:
Dorzolamide 2% (nl UK, nl USA)
￿ Prostaglandin Analogs:
Latanoprost (nl), Travoprost (nl),
Bimatoprost (nl)
￿ Adrenoceptor Agonists:
Brimonidine (nl UK), Apraclonidine
(nl)
￿ Parasympathomimetics:
Pilocarpine (nl UK, nl USA)
UK 2007
[39] Royal College of
Ophthalmologists
Guidelines for the
management of
amblyopia
Ambliopia III ￿ Refractive correction (glasses)
￿ Patching: from 2 to 6 hours per
day
￿ Atropine (nl IT, nl USA)
UK 2006
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Page 9 of 13dry eye syndrome (2), and pterygia (1), and 4 RCTs on
bevacizumab in the treatment of neovascular glaucoma
in children > 3 years (all 3 completed) and in ROP in
neonates > 5 months (1 ongoing RCT).
Among the drugs that had the most ongoing studies
were also two anti-hystamine drugs, ketotifen and bepo-
tastine, and the antibacterial moxifloxacin: these were
tested in 3 RCTs each for the treatment of allergic or
bacterial conjunctivitis in children.
EMA/FDA viewpoint
Although no ophthalmologic drugs are found in the
EMA’s priority list for studies into off-patent paediatric
medicinal products at this time, the EMA Paediatric Com-
mittee (PDCO) adopted opinions on PIPs for 12 ocular
medications, with the aim to generate the necessary qual-
ity, safety, and efficacy data to support the authorization of
these medicines for use in children.
Four drugs, cysteamine, latanoprost, voclosporin and the
recombinant human monoclonal antibody to human inter-
leukin 17A received a go-ahead for a PIP, while one, travo-
prost/brinzolamide, was refused it. In four cases, one
involving the anti-inflammatory agent bromfenac, one a
new drug, ocriplasmin, for the treatment of symptomatic
focal vitreomacular adhesion, and two the vascular
endothelial growth factor inhibitors, ranimizumab and
pegaptanib, a waiver was granted in all age groups on the
grounds that the specific medicinal product does not
represent a significant therapeutic benefit or because the
disease or condition for which the product is intended
does not occur in the specified paediatric subset(s). Finally,
2 steroid drugs, dexamethasone and triamcinolone, were
refused the granting of a product-specific waiver on the
grounds that the clinical studies cannot fulfil a therapeutic
need of the paediatric population.
By consulting the “List of the active substances
included in the work-sharing procedure in accordance
with Articles 45 and 46 of the European Paediatric Reg-
ulation, no additional data or information on their use
in the paediatric population resulted to be submitted or
requested to authorise the paediatric use of any ocular
medicinal product.
Twenty-six ocular medications were found in the Food
and Drug Administration (FDA)’s “Table of Medicines
with New Paediatric Information”, a list of drugs approved
for use in the paediatric population resulting from the pae-
diatric clinical trials performed in response to paediatric
legislative initiatives. Ten (38%) were anti-allergy medica-
tions, 8 (31%) were anti-glaucoma medications (6 of which
were not yet licensed for paediatric use in the USA), and 5
were antibacterials and combinations. The last three
agents were triamcinolone (steroid agent), lidocaine (local
anaesthetic agent), and a hypromellose combination (lubri-
cant). These drugs included approved information on use
in the paediatric population resulting from the paediatric
clinical trials performed in response to paediatric legisla-
tive initiatives.
Discussion
This article reviews ocular medication use in children,
providing a summary of their licensing status in Italy, the
UK, and the USA and analyse the amount of available
studies testing these medicines in the paediatric popula-
tion. Most of the drugs listed have only recently obtained
paediatric use approval and are now widely prescribed
for children by a growing number of clinicians [29].
However, for most of these drugs wide differences in the
licensed age groups were found and only a few are avail-
able in all three countries. Even if the Paediatric Regula-
tion in EU and USA specifically aims at giving children
the same access to authorised medicinal products suita-
ble for their use, the age approval and occasionally the
approach towards certain therapeutic problems is under
Table 3 Summary of guidelines on pharmacological therapy of ocular disease in the paediatric population (Continued)
[6] National Guideline
Clearinghause (NGC)
Best evidence statement
(BESt). Treatment of
amblyopia in children.
Amblyopia I ￿ Refractive correction (glasses)
￿ Atropine: 1 drop/day, 2 - 7 days
per week (nl IT, nl USA)
￿ Patching: from 2 to 6 hours per
day
USA 2007
[38] Royal College of
Ophthalmologists
Guidelines for the
management of
strabismus in childhood
Strabismus III ￿ Surgical interventions
￿ Refractive correction (glasses)
￿ Miotics (not specified)
UK 2007
[46] The Brazilian Society of
Pediatrics, Brazilian Council of
Ophthalmology, Brazilian
Society of Pediatric
Ophthalmology
Brazilian guidelines
proposal for screening
and treatment of
retinopathy of
prematurity (ROP)
Retinopathy of
prematurity
(ROP)
III Surgical interventions+post surgical
treatment with topical steroids/
antibiotics (not specified)
Brazil 2007
[40] Royal College of
Ophthalmologists, Royal
College of Paediatrics and
Child Health, British Association
of Perinatal Medicine & BLISS
Guideline for the
Screening and
Treatment of
Retinopathy of
Prematurity
Retinopathy of
prematurity
(ROP)
III Screening examination with
Cyclopentolate 0.5%/Phenylephrine
2.5% combination: 1drop each in 2
to 3 doses, each 5 minutes apart, 1
hour prior to examination (nl)
UK 2008
NOTE: nl: not licensed for paediatric use; IT: Italy; UK: United Kingdom; USA: United States of America
Fortinguerra et al. BMC Pediatrics 2012, 12:8
http://www.biomedcentral.com/1471-2431/12/8
Page 10 of 13the direct responsibility of National Authorities, so differ-
ences in drug licensing procedure between countries
remain. There is therefore a need for evidence-based har-
monization of drug licenses in order to guarantee equal
drug availability and access [30].
Furthermore, many ocular medications commonly
used in children still do not have paediatric dosing and
safety labelling information in any country. For example,
almost for all glaucoma medications (such as prostaglan-
din analogues and carbonic anhydrase inhibitors), pae-
diatric use is labelled “not recommended”.
At this time no paediatric RCTs were available for sev-
eral ocular medications. When available, the studies were
often limited to small case series and case reports, so more
extensive controlled trials will be needed to confirm their
safety and efficacy also in paediatric population. On the
contrary, evidence on efficacy was found for drugs that
were not licensed for children, such as tetracycline and
bupivacaine.
In spite of the fact that no ophthalmologic drugs are
found in the EMA’s priority list, several drugs were
recently studied in paediatric clinical trials in the European
countries and the USA. In particular, the ongoing research
is examining the potential use of intravitreally injected
anti-VEGF drugs, such as bevacizumab, successfully used
in adults with diabetic retinopathy or age-related macular
degeneration (AMD), a cause of a severe vision loss
among the aging population in many western countries
[31,32]. These drugs could now also be used in paediatric
vitreoretinal diseases, as shown by recent studies on intra-
vitreal injection of bevacizumab for the treatment of ROP,
the leading cause of childhood blindness [33-37].
Moreover, the available guidelines on the pharmacologi-
cal management of eye diseases in the paediatric popula-
tion often recommend the use of medications not licensed
or investigated in children, especially for the management
of glaucoma (such as prostagliandin analogs) or acute
bacterial conjunctivitis (such as steroids and antibiotics
combinations). An effort to stimulate research and clinical
development is therefore needed also for them, in order to
guarantee medicines that have been proven to be of bene-
fit also in paediatric patients.
Many good ethical and economical reasons exist for
limiting paediatric clinical trials, while guaranteeing
appropriate conclusions. Because of the characteristics of
the paediatric population, limited information is also
available regarding the side effects related to ocular medi-
cation use in children [38]. As the number and variety of
ocular medications has increased and the number of clin-
icians involved in their prescription has grown, the risk
of systemic adverse reactions may also increase [39,40].
When prescribing ocular medications in children, physi-
cians should therefore carefully consider their risk/bene-
fit profile, referring to details of labelling for paediatric
use, such as the age of the child for whom the drug is
approved, and be aware of their potentially serious sys-
temic side effects [5].
Some strategies for reducing systemic absorption and
toxicity should be followed whenever possible. First of all,
the lowest available dosage of medication necessary to
achieve a therapeutic benefit while minimizing risk should
be used. Secondly, since different formulations may have
different degrees of systemic absorption, formulations with
lower systemic absorption, which may be more suitable
for use in children, should be used. Ophthalmic gel or
ointment, for example, has been found to have reduced
systemic absorption compared to the ophthalmic solution
[28]. In addition, paediatric patients should be monitored
closely during and after treatment for local and systemic
side effects [29].
The present findings suggest that access to, and
rational use of, ocular medications in the paediatric
population continue to present a considerable challenge.
Paediatric clinical trials are important for defining how
infants and children respond to medications and for
identifying age-specific toxic effects [41]. While recent
legal and economic incentives in both Europe and the
USA stimulate research to obtain more data regarding
dosing, efficacy, and safety of medicines used in chil-
dren, problems remain in obtaining adequate evidence
[42]. In this context, there is a pressing need for further
clinical research to improve the quality, efficacy, and
safety of ocular medications offered to paediatric
patients. Clinical research must be carried out using
appropriate methodologies ( e . g .s t u d yd e s i g n ,s a m p l e
size, randomization, and blinding) [38] also (and in par-
ticular) in the paediatric ophthalmic area, where effec-
tive up-to-date treatments, and additional research and
education on use in children, remain priorities [43].
Conclusion
European and American legislation has established that
children should have the same rights as adults to receive
medicines that have been proven to be of benefit and
that are unlikely to cause serious toxicity [44]. Even if the
legislative initiatives in both Europe and the USA empha-
sizes the importance of large clinical trial in children,
prioritizing the medicines to be studied on the basis of
children’s needs [45], differences between countries in
drug licensing procedures, and occasionally in the
approach towards certain therapeutic problems, may be
quite significant [30]. A formulary containing common
“paediatric” evidence-based safety and efficacy informa-
tion could be a useful tool for improving the rational use
of drugs in children and adolescents, harmonizing inter-
country drug regulations and availability [46].
In addition, recommendations from high quality RCTs
and systematic reviews, and effective knowledge translation
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Page 11 of 13strategies are essential to clinicians and policy makers in
planning changes in practice that could ultimately improve
patient- and system-related outcomes. All such considera-
tions are priorities for an area, such as ophthalmic drug
therapy in children, that is lacking evidence.
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